IFNAR Activator

SMU-3k is a STING activator and PD-L1 inhibitor, with a PD-L1 IC₅₀ of 106 nM, a K_D of 386 nM for human PD-L1, and a K_D of 352 nM for murine PD-L1. SMU-3k activates the STING pathway, induces phosphorylation of TBK1 and IRF3, and promotes the expression of IFN-β, IL-6 and CXCL10. SMU-3k blocks the PD-1/PD-L1 interaction, reduces PD-L1 levels and induces PD-L1 internalization. Through dual immunomodulation, SMU-3k exerts synergistic tumor growth inhibitory effects in a mouse colon cancer model. SMU-3k can be used for the research of colon cancer.

Centaurein, a flavonoid, is an IFN-γ promoter enhancer. Centaurein up-regulates the activity of NFAT and NF-κB enhancers. Centaurein increases the IFN-γ expression in T and NK cells and the serum IFN-γ level in mice. Centaureidin completely relaxes the contractions in intact rat aortic rings. Centaurein effectively protects mice against Listeria infection^[1][2][3][4].

MEDI-5083 is an Fc fusion protein that targets CD40 and is a CD40 agonist. MEDI-5083 stimulates CD40 signaling via NF-κB activation. MEDI-5083 upregulates MHCII, CD80, and CD86 expression, induces pro-inflammatory cytokine secretion, and enhances IFN-γ secretion by memory CD8⁺ T cells. MEDI-5083 can be used for the research of melanoma, colon carcinoma, and advanced solid tumors^[1][2].

TP1L is a potent and selective T-cell protein tyrosine phosphatase (TC-PTP) PROTAC degrader, with a DC₅₀ value of 35.8 nM. TP1L elevates the phosphorylation level of TC-PTP substrates including pSTAT1 and pJAK1. TP1L selectively enhances IFN-γ signaling and increases MHC-I expression. TP1L activates TCR signaling through increases phosphorylation of LCK. TP1L enhances CAR-T cell mediated tumor killing efficacy through activation of the CAR-T cells. TP1L can be used for the study of cancer. (Pink: TC-PTP ligand: (HY-138964), Blue: E3 ligase CRBN Ligand (HY-A0003), Black: Linker: (HY-140002)).

Cridanimod sodium is an antiviral agent that induces interferon production in mice. Cridanimod can be utilized in antiviral research.

Centaureidin is an orally active IFN-promoter that can be isolated from Bidens pilosa with an EC₅₀ of 0.9 μg/mL. Centaureidin activates the Rho signal pathway, leading to actin and tubulin disassembly, and resulting in dendrite retraction and stress fiber formation in melanocytes. Centaureidin shows high tumor cell growth inhibitory activities. Centaureidin significantly inhibits paw edema in mice^{[1][2][3][4][5]}.

PROTAC HPK1 Degrader-4 is an orally active HPK1 PROTAC degrader and immune activator, with DC₅₀ values of 3.16 nM and 72.59 nM in Jurkat cells and PBMCs, respectively. PROTAC HPK1 Degrader-4 induces degradation via the ubiquitin-proteasome system, downregulates the HPK1-SLP76 signaling pathway, reduces the phosphorylation level of SLP76 (S376), and promotes immune activation. PROTAC HPK1 Degrader-4 can be used in the research of colorectal cancer and B-cell lymphoma.

cAIMP (Cyclic Adenosine-Inosine Monophosphate) is an effective synthetic cyclic dinucleotide. cAIMP activates IRF and NF-κB in the THP1 human monocyte reporter cell line (THP1-Dual). cAIMP induces the secretion of IFNs and pro-inflammatory cytokines in vitro in human blood, with an EC₅₀ of 6.4 μmol/L.

Adenosine receptor antagonist 6 is an orally active and selective A_2A adenosine receptor (A_2AAR) antagonist, with a K_i of 19.18 nM. Adenosine receptor antagonist 6 inhibits 5’-N-ethylcarboxamide adenosine (NECA) (HY-103173)-mediated cAMP production (IC₅₀ = 0.089 μM) and immunosuppression, while promoting IL-2 and IFN-γ secretion. Adenosine receptor antagonist 6 abolishes the immunosuppressive effects of adenosine on T-cell activation and cytokine release. Adenosine receptor antagonist 6 inhibits tumor growth in a CT26/MC38 xenograft model. Adenosine receptor antagonist 6 can be used for the study of colon cancer.

5-Androstenetriol is a systemic radiation protector that can boost the host's immunity, leading to increased resistance to infections. 5-Androstenetriol can raise levels of IL-2, IL-3, and IFN, while countering the immunosuppressive effects of Hydrocortisone (HY-N0583).

PTPN2-IN-2 is a potent and orally active PTPN2 inhibitor (IC₅₀ = 7.05 nM) that enhances the IFN-γ signaling pathway. PTPN2-IN-2 inhibits PTP1B with an IC₅₀ of 9.88 nM. PTPN2-IN-2 inhibits tumor growth, promotes the activation and infiltration of tumor immune cells in a B16-OVA mouse model. PTPN2-IN-2 can be used for the research of melanoma.

NUCC-0227579 is a VHL-recruiting PROTAC degrader targeting CD73, with a DC₅₀ of 0.32 μM. NUCC-0227579 synergistically mediates CD73 degradation through the ubiquitin-proteasome pathway and the lysosomal pathway. NUCC-0227579 inhibits the conversion of AMP to adenosine, abrogates adenosine-mediated immunosuppression, upregulates the activities of the NF-κB and NFAT pathways, and enhances the secretion, activation and proliferation levels of IFN-γ and TNF-α. NUCC-0227579 downregulates NAD⁺ synthesis in tumor cells, and inhibits the proliferation, migration and adhesion abilities of tumor cells under glutamine-deficient conditions. NUCC-0227579 significantly suppresses tumor growth in a humanized NSG mouse model of triple-negative breast cancer.

M802 is an anti-HER2/CD3 bispecific antibody, with a K_d of 0.578 nM for human HER2 and a K_d of 71.2 nM for human CD3. M802 inhibits the PI3K/AKT and MAPK signaling pathways, suppresses tumor cell proliferation, activates caspase-3, and promotes tumor cell apoptosis (apoptosis). M802 recruits and activates CD3-positive immune cells, mediates cytotoxicity against HER2-positive tumor cells, and induces immune cells to secrete IFN-γ, TNF-α, IL-2 and IL-6. M802 exhibits anti-tumor efficacy in mice with gastric cancer xenografts. M802 can be used in research related to HER2-positive breast cancer, HER2-positive gastric cancer and other cancers. The recommended isotype control is human IgG1 kappa (HY-P99001).

MSP-1 P2 is a synthetic peptide of merozoite surface protein-1 (MSP-1). MSP-1 P2 stimulates umbilical cord blood lymphocytes to produce IFN-γ and IL-13, and this immune response is primarily mediated by CD4+ T cells. MSP-1 P2 can be used as a specific antigen stimulus to detect T cell responses and cytokine levels.

KRAS G12C Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12C oncogenic mutation. KRAS G12C Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12C Peptide can be used for the study of immune responses against KRAS G12C-mutant tumors.

PROTAC HPK1 Degrader-7 (compound D02) is a potent and selective PROTAC HPK1 degrader with an DC₅₀ of 3.07 nM. PROTAC HPK1 Degrader-7 exhibits selectivity over GLK. PROTAC HPK1 Degrader-7 induces HPK1 degradation in a CRBN- and proteasome-dependent manner. PROTAC HPK1 Degrader-7 inhibits SLP-76 phosphorylation, induces IL-2 and IFN-γ secretion in human primary T cells. PROTAC HPK1 Degrader-7 can be used for immunology research.

CLEC5A-IN-1 is an inhibitor that binds to CLEC5A, with a K_d value of 277 nM. CLEC5A-IN-1 inhibits HBV replication. CLEC5A-IN-1 induces the production of IFNα and IFNβ. CLEC5A-IN-1 reduces serum HBsAg and HBV DNA levels, as well as hepatic HBcAg levels, in HBV-infected animals. CLEC5A-IN-1 increases the positive rate and levels of serum HBsAb in HBV-infected animals. CLEC5A-IN-1 can be used for the research of hepatitis B.

DF6002 (BMS-986415) is a monovalent IL-12 immunoglobulin Fc fusion protein. DF6002 can promote sustained IFN-γ responses while reducing toxicity. DF6002 binds specifically to IL-12R on CD4⁺ T cells, CD8⁺ T cells, NK cells, and B cells. DF6002 can be used for the research of solid tumors .

NHWL071065 is a CRBN-targeting IKZF1/IKZF3 molecular glues degrader. NHWL071065 selectively degrades IKZF1 and IKZF3 in lymphoma cells via the ubiquitin-proteasome pathway. NHWL071065 inhibits the proliferation of lymphoma cells. NHWL071065 downregulates proteins involved in cytoskeleton assembly, cell adhesion and immune regulation in cells, while upregulating proteins related to the type I IFN signaling pathway. NHWL071065 can be used in the research of lymphoma.

Vadimezan (Standard) (DMXAA (Standard)) is the analytical standard of Vadimezan (HY-10964). This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.